

Docket No.: 0010-1066-0

APR 1 1 2001
TECH CENTER 1600/2900

ATTORNEYS AT LAW

**OBLON** 

**SPIVAK** 

**McClelland** 

MAIER

P.C.

Norman F. Oblon (703) 413-3000 NOBLON@OBLON.COM

DANIEL J. PEREIRA (703) 413-3000 DPEREIRA@OBLON.COM \*REGISTERED PATENT AGENT

ATTENTION: BOX SEQUENCE ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

For:

RE:

Application Serial No.: 09/459,573

Applicant(s): Vitaliy Arkadievich LIVSHITS et al

Filing Date: December 13, 1999

METHOD FOR PRODUCING L-AMINO ACID

Group No.: 1652
Examiner: TUNG
Attn: BOX SEQUENCE

SIR:

Attached hereto for filing are the following papers:

## NOTICE TO COMPLY PRELIMINARY AMENDMENT SEQUENCE LISTING COMPUTER-READABLE SEQUENCE LISTING (DISKETTE)

Our check in the amount of \$\_\_\_\_\_ is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Oblon Registration No. 24,618 Attorney of Record

Daniel J. Pereira, Ph.D. Registration No. 45,518

22850

PECEIVED

DIGHT 3 THO THICK

ECH CENTER (600/2900, 200 2)

DATE: AMDERICAL

1755 JEFFERSON DAVIS HIGHWAY ■ FOURTH FLOOR ■ ARLINGTON, VIRGINIA 22202 ■ U.S.A. TELEPHONE: 703-413-3000 ■ FACSIMILE: 703-413-2220 ■ www.oblon.com

## No.: 09/459,573

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

<i>y</i> .	na na	1	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
R	DEW	<b>%</b> .	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	X	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
			A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
			The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
		6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
		7.	Other:
Applicant Must Provide:			
	X	Ar	initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	X		n initial or <u>substitute</u> paper copy of the "Sequence Listing", as well-as an amendment directing its entry to the specification.
	X	аŗ	statement that the content of the paper and computer readable copies are the same and, where oplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 325(b) or 1.825(d).
	For	- q	uestions regarding compliance to these requirements, please contact:

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support